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Abstract
Objective: Intra-articular drug delivery systems still suffer from too short-lasting effects. Magnetic particles retained in the joint
using an external magnetic field might prolong the local release of an anti-inflammatory drug. For the purpose,
superparamagnetic iron oxide nanoparticles (SPIONs) and dexamethasone 21-acetate (DXM) were co-encapsulated into
biodegradable microparticles.
Methods: Poly(D,L-lactide-co-glycolide) microparticles embedding both SPIONs and DXM were prepared by a double emulsion
technique. The formulation was optimized in two steps, a screening design and a full factorial design, aiming at 10-mm particle
diameter and high DXM encapsulation efficacy.
Results: The most significant parameters were the polymer concentration, the stirring speed during solvent extraction and the
extractive volume. Increasing the polymer concentration from 200 to 300mgml1, both the microparticle mean diameter and the
DXM encapsulation efficacy increased up to 12mm and 90%, respectively. The microparticles could be retained with an external
magnet of 0.8 T placed at 3mm. Faster DXM release was obtained for smaller microparticles.
Conclusion: The experimental set-up offered the tools for tailoring a formulation with magnetic retention properties and DXM
release patterns corresponding to the required specifications for intra-articular administration.
Keywords: Magnetic microparticles, dexamethasone, experimental design, drug release, superparamagnetic iron oxide
nanoparticles (SPION)
Introduction
Rheumatic diseases, such as arthritis or osteoarthritis,
are severe conditions characterized by joint inflamma-
tion and cartilage erosion, respectively, leading in both
cases to a gradual loss of the mobility of the patients
and to an impairment of their quality of life. Regarding
the treatment of these affections, two main approaches
are generally adopted: the use of symptomatic drugs
aiming at pain relief and that of drugs fighting
against the cause of the disease, when known.
Anti-inflammatory drugs, both non-steroidal and
steroidal, belong to the first category. However, they
are usually short-acting substances, requiring repeated
administration at high doses, resulting in severe
systemic side effects. In this respect, longer-acting
medications, generally corticosteroids (Gaffney et al.
1995; Raynauld et al. 2003) administered by intra-
articular injections, have represented a major break-
through in the treatment of arthritis or osteoarthritis
(Gerwin et al. 2006). Clinical tests have shown,
however, that intra-articular corticosteroids, despite
their net efficacy, are not devoid of side effects. For
example, because of their crystalline structure, a
condition referred to as crystal-induced arthritis was
described in 10% of the patients receiving an intra-
articular injection (Tosu 1992; Moore 2005). Moreover,
due to lymph drainage (Gerwin et al. 2006) or
macrophage uptake, the residence time of corticosteroid
molecules in the joint is very small, requiring frequent
intra-articular injections in order to obtain a sustained
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clinical result. The complications of such frequent
injections in terms of infections or joint instability,
although rare, remain severe (Moore 2005). All these
aspects emphasize the need to develop drug delivery
systems allowing the sustained release of the active
substance in order to reduce the frequency of the intra-
articular injections together with the related potential
deleterious effects.
In this respect, drug delivery systems, such as
liposomes (Metselaar et al. 2006), nano- and micro-
particles (Tuncay et al. 2000; Bozdag et al. 2001;
Horisawa et al. 2002a), all embedding anti-inflamma-
tory substances, have been designed for intra-articular
administration in the attempt to reduce the systemic
side effects observed after the oral or i.v. administration
of the respective anti-inflammatory substances.
However, the efficacy of these vectors was hindered
by the fact that they were rapidly cleared out of
the joint.
Magnetic microparticles loaded with corticosteroids
could represent a valuable way of addressing all the
above-mentioned issues. First, because the drug is
present in a solubilized form in the joint, the deleterious
crystal-induced pain could be avoided. Secondly, due to
their magnetic nature, these systems could be retained
in the joint with an external magnetic field, resulting in
an increased residence time in the articular cavity,
allowing the active substance to be released and to act
locally. Superparamagnetic iron oxide nanoparticles
(SPIONs) can be used as magnetic material. Their
biocompatibility with the tissues of the joint, notably
with the synovial membrane, was shown by Schultze
et al. (2005) in sheep. Moreover, these magnetic
nanoparticles are already used in humans as super-
paramagnetic contrast agents (Kopp et al. 1997) and
are thus expected to produce neither immunogenic nor
inflammatory reactions.
The aim of this study was thus to formulate
biodegradable magnetic microparticles for intra-articu-
lar delivery of the anti-inflammatory steroid dexa-
methasone 21-acetate (DXM). The choice of this ester
was based on previous studies. It could be demon-
strated (results not shown) that the use of dexametha-
sone sodium phosphate was not possible, due to its
reaction with the free iron ions, leading to precipitation
in the internal aqueous phase, nor was it possible to use
dexamethasone base, due to the formation of dexa-
methasone crystals, limiting its encapsulation efficacy.
The formation of dexamethasone crystals in this case
has already been reported by Gomez-Gaete et al.
(2007). Few studies have been published regarding the
separate encapsulation of dexamethasone or of SPIONs
into polymeric particles (Beck et al. 2007; Okassa et al.
2007). Concerning the encapsulation of both dexa-
methasone and SPIONs into microparticles, the only
report is that of Ghassabian et al. (1996) who prepared
dexamethasone sodium phosphate-containing magnetic
albumin microspheres by an emulsion in cottonseed oil.
These particles showed a very rapid release pattern, all
substance being released within 3 h. Moreover, the
studies mentioning the co-encapsulation of SPIONs
and another drug are also few, proving that research in
this domain is still at the initial stage. Cheng et al.
(2006) prepared magnetic PLGA microparticles for the
oral delivery of insulin. Magnetic PLLA nanoparticles
encapsulating chemotherapeutic drugs, suitable for
tumour imaging and drug delivery, were formulated
by Hamoudeh et al. (2007), but also by Hu et al.
(2006). Poly("-caprolactone) magnetic nanoparticles
containing cisplatin or gemcitabime were also prepared
(Yang et al. 2006). Timko et al. (2006) encapsulated
indomethacin into poly(D, L-lactide) magnetic nano-
particles for magnetic drug targeting (Zavisova et al.
2007).
Although some magnetic microparticles have already
been prepared for magnetically triggered oral delivery,
imaging or magnetic drug targeting, to the authors’
knowledge there is no example in the literature of
magnetic particles intended for intra-articular delivery.
The requirements for intra-articular magnetic retention
are actually distinct from these above applications.
To ensure a maximum retention efficacy, one needs to
maximize the balance between magnetic and viscous
forces, thus aiming at sufficiently large particles. One
also aims at injecting only small quantities of iron oxide
to the joint, still ensuring magnetic particle retention,
while limiting the possible side effects due to large iron
oxide content (Weissleder et al. 1989).
Concerning the intra-articular administration, the
literature provides little information on the most
suitable particle size. In this respect, various research
teams have studied microparticles with mean diameters
ranging from the nanometer scale up to 200–300 mm
(Ratcliffe et al. 1987; Horisawa et al. 2002a,b, Liggins
et al. 2004). It has been demonstrated that particles with
mean diameters of more than 20 mm are not captured by
synoviocytes and macrophages, while smaller micro-
particles can be internalized. The process of internaliza-
tion could however be of great importance if the
targeted substance needs to act intra-cellularly, such as
corticosteroids, which have nuclear receptors. Based on
all these studies and in view of future clinical applica-
tions, one considers that the most useful size would be
10 mm in order to limit the possible inflammatory
reactions in the articular joint (Horisawa et al. 2002b).
Concerning the biodegradable polymer matrix of the
microparticles, many materials have been investigated
for the intra-articular administration: poly(lactic acid),
poly(butyl cyanoacrylate), gelatin, albumin, polycapro-
lactone, DL-lactide/glycolide copolymer (Ratcliffe et al.
1987; Horisawa et al. 2002a,b, Liggins et al. 2004). Due
to its biocompatibility and wide acceptance, DL-lactide/
glycolide copolymer (PLGA) was chosen as the micro-
particle matrix.
Practically, the corticosteroid dexamethasone
21-acetate and SPIONs, as ferrofluid, were
340 N. Butoescu et al.
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co-encapsulated into PLGA biodegradable microparti-
cles and the formulation process was optimized by
means of the experimental design approach. First of all,
in order to identify the most relevant parameters
affecting the formulation process, a screening design
was performed. Afterwards, varying only the most
relevant parameters, an optimization design was
performed in order to find the best conditions leading
to the highest DXM loading correlated with the highest
encapsulation efficacy. Microparticles were character-
ized in terms of size, DXM loading and DXM
encapsulation efficacy, SPION content and, last but
not least, magnetic retention and DXM release
patterns.
Materials and methods
Materials
Poly(D,L-lactide-co-glycolide) (PLGA 75:25, inherent
viscosity 0.2 dl g1) was provided by Boehringer
Ingelheim (Germany) (Resomer RG 752S).
Dexamethasone 21-acetate was purchased from Sigma
Aldrich (Switzerland). Poly(vinyl alcohol) (PVA) was a
gift from Clariant GmbH (Germany) (Mowiol 4-88,
hydrolysis degree 88% and molecular weight of
26 kDa). SPIONs were prepared according to the
method described by Chastellain et al. (2004). They
were used in the process as a suspension, referred to as
ferrofluid, with an iron content of 10.3mgml1, as
assessed by atomic absorption. Ethyl acetate, acetoni-
trile and ethanol were of analytical grade. The purified
water used during the experiments was obtained with a
MilliQ system (Millipore, Switzerland).
Preparation of microparticles
The microparticles were prepared by a double emul-
sion-solvent extraction method. Briefly, 1ml of organic
phase containing either 200, 250 or 300mgml1 RG
752S and 10mgml1 DXM in ethyl acetate added with
10% ethanol as a co-solvent (DXM solubility in the
solvent mixture is 19mgml1, as determined by HPLC)
was emulsified with 0.15ml of ferrofluid (10mgml1
iron) by means of a sonicator for 10 s (VibraCellTM VC
50T, Sonics and Materials, USA). This primary
emulsion was emulsified with 2ml 2% PVA solution
using a T25 Ultra-Turrax (IKA Labortechnik,
Germany) for 1min at 8000 rpm. This final emulsion
was then poured into 10, 15 or 20ml of water and
mechanically stirred for 4 h at room temperature at 400,
700 or 1000 rpm (Eurostar Digital, IKA labortechnik,
Germany). The resulting microparticles were separated
by using a Jouan BR 3.11 centrifuge (IG, Switzerland),
washed 3 times with MilliQ water, freeze-dried
(Modulyo Freeze Dryer, Edwards, Switzerland) and
finally stored at 4C.
Note that the values of the above-mentioned
technological parameters were those used in the full
factorial design, performed after the screening design.
During the screening design, more factors were varied,
notably PLGA concentration, ferrofluid volume, exter-
nal aqueous phase volume, PVA concentration in the
external aqueous phase, stirring speed and stirring time
during the final emulsification step and extractive
volume. The low and high levels of these nine factors
are presented in Table I. Among these nine factors,
three of them turned out to be relevant to the
formulation process and, hence, they were subsequently
used in the full factorial design. The low levels and the
high levels of these three factors are presented in
Table II.
Microparticle characterization
Size measurements were performed using light scatter-
ing (Mastersizer S, Malvern, UK) after dispersing the
particles in water and the sizes were expressed as D[4;3].
Scanning electron microscopy was performed on
gold-coated freeze-dried samples (Balzers SCD 004
Sputter Coater) with a JEOL JSM-6400 microscope
(Tokyo, Japan) at an accelerating voltage of 10–15 kV
in order to determine the surface morphology of the
particles.
Table I. Parameters of the screening design with their low and high
levels.
Factor Low level High level
PLGA concentration
(mgml1)
200 300
Ferrofluid volume (ml) 0.10 0.20
External aqueous phase
volume (ml)
2 4
PVA concentration in
external aqueous
phase (%)
2 5
Stirring speed during final
emulsification step (rpm)
8000 9750
Stirring time during final
emulsification step (min)
1 2
Extractive volume (ml) 10 20
PVA concentration in
extraction medium (%)
0 0.60
Stirring speed during
solvent extraction
step (rpm)
400 1000
Table II. Factors of the full factorial design with their low and high
levels.
Factor Low level High level
PLGA concentration (mgml1) 200 300
Stirring speed during solvent
extraction step (rpm)
400 1000
Extractive volume (ml) 10 20
Co-encapsulation of dexamethasone 21-acetate and SPIONs into biodegradable polymeric microparticles 341
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Magnetic retention of the microspheres was assessed
using the device depicted in Figure 1 and equipped with
a Nd-Fe-B magnet generating a magnetic field of 0.8 T.
The percentage of retained microspheres was calculated
by dividing the final microparticle mass (after discard-
ing the remaining suspension and freeze-drying the tube
content) by the initial one.
DXM content of the microparticles was measured by
HPLC, using a 100-5 C18 Nucleosil column (250/4.6,
Macherey Nagel), an acetonitrile:water 1:1 mobile
phase, a flow rate of 0.8mlmin1 and detection at
254 nm, after solubilization of the particles in acetoni-
trile. The suspension was centrifuged at 21 000 rpm in
order to separate the insoluble SPIONs from the DXM-
containing solution.
The DXM encapsulation efficacy and DXM loading
into the microparticles were calculated based on the
following equations:
DXM encapsulation efficacy ¼wtDXMentrapped
wtDXMused
 100
ð1Þ
DXMloading ¼ wtDXMentrapped
wtmicroparticles used for dosing
 100
ð2Þ
The solid mass obtained after microparticle dissolution
in acetonitrile was then used to assess the SPION
content. This was determined by a spectrophotometric
method based on the formation of a red complex
between Feþ3 and o-phenanthroline. Briefly, the solid
was left to dry overnight and then treated with 6M HCl
in order to solubilize Fe3O4. An aliquot of this solution
was taken and treated with 1% hydroxylamine hydro-
chloride aqueous solution to reduce Fe3þ ions into
Fe2þ. A 200 gL1 sodium acetate solution was then
added and finally 0.015M o-phenanthroline hydro-
chloride solution was added in order to obtain the red
complex. The absorbance was immediately measured at
510 nm using a spectrophotometer.
DXM release kinetics was conducted by placing
10–15mg of microparticles in 50ml 15mM PBS pH 7.4
with 2mM sodium azide as a preservative agent and
0.5% polysorbate 80, to increase the solubility of
DXM and the wettability of the microparticles
(DXM solubility in the release medium is
0.042mgml1, as determined by HPLC). The quantity
of particles was adjusted in order to have sink
conditions during the duration of the experiment. The
suspension was continuously horizontally shaken at
120 rpm and 37C in a GFL-3033 shaker (Burgwedel,
Germany). At defined time intervals, aliquots of 0.5ml
were withdrawn, centrifuged in order to separate
microparticles, which were returned to the release
medium, and assayed for DXM using HPLC. The
withdrawn volume was replaced by fresh PBS.
All experiments were performed in triplicate.
Screening design
In order to determine the influence of the most relevant
factors on microparticle size, DXM loading and DXM
encapsulation efficacy, a screening design was
performed. The factors of the design were chosen
based on preliminary experiments and bibliography
data. A Plackett-Burman matrix was used to study the
influence of nine factors in 12 experiments (Khan et al.
2000). In order to estimate the variability of the
experimental results, four centre points were added to
the design. The number of the degrees of freedom
available to estimate the error was six. The set-up was
completely randomized, in order to minimize the effect
of possible disruptive variables. The low levels and the
high levels of the parameters studied in this experi-
mental design are presented in Table I. The studied
PLGA concentrations varied between 200–300mgml1,
because, based on preliminary experiments, these values
allowed one to obtain microparticles with a diameter
10 mm and a high DXM encapsulation efficacy.
Moreover, another reason for selecting these PLGA
concentrations was the ratio of polymer:DXM. In order
to ensure a sufficient DXM solubility in the organic
phase, a maximal polymer concentration of
300mgml1 was set, resulting in microparticles with
DXM loading suitable for future i.a. clinical applica-
tions. On the other hand, if polymer concentration is
below 200mgml1, microparticle size is in the range of
nanometer scale, which hinders the encapsulation of an
optimal SPION quantity. Besides PLGA concentration,
eight other factors were screened in order to determine
the best conditions leading to the highest DXM
encapsulation efficacy combined with the highest
DXM loading. The studied ferrofluid volume varied
between 0.1–0.2ml, which represented 10–20% of the
organic phase, these being the most common ratios
between the internal aqueous and organic phases.
The external aqueous phase volume, the PVA concen-
tration in the external aqueous phase, the stirring speed
and the time during the final emulsification step
were chosen based on the preliminary experiments.
The volume of the extraction aqueous phase
Figure 1. Apparatus for the assessment of microparticle
magnetic retention.
342 N. Butoescu et al.
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was between 10–20ml, because at the beginning of the
double emulsion, droplets need to harden progressively
in order to avoid precipitation of the DXM out of the
microparticles. After 10min, the same extraction
aqueous medium was added to a final extractive
volume of 50ml for all experiments. This suspension
was then stirred for 4 h, for complete solvent evapora-
tion. All the conditions of the 16 batches of the
screening design are presented in Table III.
Factorial design
The screening design was a means to identify the most
significant factors in the process and to rank them from
the point of view of their importance on the micro-
particle formulation. Subsequently, a full factorial
design was carried out aiming at optimizing the
formulation with respect to these sole factors.
A group of eight experiments was designed and two
centre points were added in order to estimate the
experimental error. In a similar manner as for the
screening design, the three factors had a high and a low
level (Table II). The plan was completely randomized
and the sequence of runs is presented in Table IV.
In both the screening and the factorial designs, the
responses considered were: DXM loading, DXM
encapsulation efficacy and microparticle size. Data
were treated using the StatGraphicsTM software. Here,
in order to define the optimal conditions for the
microparticle formulation process, the approach of
maximization of a desirability function was chosen. The
desirability function method is based on that fact that a
process is acceptable only if all its quality characteristics
are between the limits of acceptability. The acceptable
limits of the quality characteristics of our process are
listed in Table V.
From these designs, one could determine the ‘most
desirable’ experiment from the point of view of
the microparticle size, DXM loading and DXM
encapsulation efficacy. Nevertheless, additional criteria
were considered for the selection of the final formula-
tion, namely SPION content, magnetic retention and
DXM release.
Results and discussion
Screening design
The screening design has been carried out to determine
the order of significance of the nine parameters for the
microparticle formulation. The standardized Pareto
charts presented in Figures 2–4 show the estimated
effects of the parameters on the response variables in
descending order of their importance. The length of
each bar is proportional to the standardized effect,
which is equal to the estimated effect divided by
the standard error. The vertical line delimits which
parameters are significant at a confidence level of 95%.
It is important to notice that the experimental data fits
the mathematical model well for all three studied
response variables, with R2 values of 0.9040, 0.9392
and 0.8324 and adjusted R2 for the degrees of freedom
of the error with values of 0.7602, 0.8481 and 0.5810,
respectively, for DXM loading, DXM encapsulation
efficacy and particle size.
The significant parameters on DXM loading are, in
decreasing order, the extractive volume, PLGA
concentration, stirring speed during the extraction
step and the external aqueous phase volume, as
depicted in Figure 2. All the other parameters are not
significant at a confidence level of 95%. The extractive
volume has a positive effect on DXM loading, meaning
that when the extracting volume increases, the DXM
loading increases. In fact, a larger extractive volume can
lead to a more rapid diffusion of the solvent out of the
microparticles, resulting in earlier microparticle
hardening, with increased DMX entrapping efficiency.
Increasing the PLGA concentration in the organic
phase from 200 to 300mgml1 results in the decrease of
the DXM loading due to a lower PLGA:DXM ratio,
the DXM concentration in the organic phase remaining
constant for all experiments (10mgml1). The increase
in the stirring speed during the extraction step leads to
increased DXM loading into the microparticles. One
possible explanation could also be the more rapid and
efficient hardening of microparticles when a higher
stirring speed is applied. The fourth significant factor
on the DXM loading is the external aqueous phase
volume. Indeed, an augmentation in the DXM loading
is observed when the external aqueous phase volume
augments, which is also related to rapid microparticle
hardening.
Regarding the influence of the studied parameters on
DXM encapsulation efficacy, the same four parameters
as for DXM loading appear to be significant according
to Figure 3. The only difference compared to DXM
loading is their respective order, the most important
factor being PLGA concentration in the organic phase.
Figure 3 shows that increasing PLGA concentration
results in an increase in DXM encapsulation efficacy.
This can be related to the fact that increasing PLGA
concentration has the consequence that the DXM
molecules are surrounded by more polymer macro-
molecules, leading to better encapsulation.
The concentration of PLGA in the organic phase has
a positive influence on the particle size. The presence of
a higher PLGA concentration in the organic phase
leads to a higher viscosity, producing larger and more
stable primary emulsion droplets. An increase in
microparticle size is also related to an increase in the
external aqueous phase volume, according to Figure 4.
This result is in accordance with previous works,
reporting an increase in microparticle size with the
external aqueous phase volume (Pean et al. 1998).
One possible explanation would be that a larger
external aqueous phase volume added to the same
Co-encapsulation of dexamethasone 21-acetate and SPIONs into biodegradable polymeric microparticles 343
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volume of organic phase results in a decrease in the
stirring efficacy, leading to coarser emulsion droplets,
which will harden into larger microparticles.
As a result of the screening experiment, the three
significant parameters—notably PLGA concentration,
external aqueous phase volume, stirring speed during
emulsification—were retained for the subsequent opti-
mization study.
Factorial design
The effects of the three retained parameters and their
interactions were then investigated in more detail using
a full factorial design. The three factors (PLGA
concentration, extractive volume and stirring speed
during the emulsification step) were varied, while all
others were kept at the constant values quoted in the
Materials and methods section. On examination of
Table IV, it is observed that the microparticle size can
be increased up to 3 times when increasing the PLGA
concentration from 200 to 300mgml1. The encapsula-
tion efficacy of DXM for all 10 batches was greater
than 70% and due to optimization, DXM loading
could be increased by almost 50%.
The results obtained from the full factorial design for
the microparticle size confirms that only the PLGA
concentration has a significant effect at the 95%
confidence level (Figure 5): at higher PLGA concentra-
tions, the particle size increases, demonstrated also by
the SEM photomicrographs of Figure 6. From these
pictures, one can also see that the microparticles are
spherical, quite homogeneous in size, with a non-
porous surface. Moreover, the inner structure of the
microparticles was studied also by SEM and the image
can be seen in Figure 7. By analysing this image, one
can conclude that the microparticles do not have a
porous inner structure. Some of the particles are empty
(capsules) and others have only a few small cavities, but
no relationship between the size and the inner structure
could be established.
As for the DXM encapsulation efficacy, the most
significant factors are the PLGA concentration in the
organic phase and the volume of the extracting phase
(Figure 5). Moreover, at the 95% confidence level, two
interactions are also significant, as depicted in Figure 8,
meaning that the effect of each of the two interactive
factors is dependent on the level of the other one.
In particular, from Figure 8(a) it can be inferred that at
400 rpm, the DXM encapsulation efficacy increases
more steeply when PLGA concentration changes from
200 to 300mgml1 than at 1000 rpm. As for the
interaction between the PLGA concentration and the
extracting volume, Figure 8(b) shows that when using
10ml extracting volume, the DXM encapsulating
efficacy increases more rapidly when PLGA concentra-
tion augments from 200 to 300mgml1 than when
using 20ml extracting volume.
Regarding DXM loading, two out of the three
factors have a significant effect: PLGA concentration
and extracting volume (Figure 5). Actually, by increas-
ing the PLGA concentration, a decrease in the DXM
loading is noted, due to the fact that the DXM
concentration in the organic phase remains the same
because of its limited solubility, while the PLGA
concentration augments.
Finally, by using the StatGraphicsTM software,
a multi-response optimization was performed, based
on the maximization of a desirability function. This
procedure allows the determination of the combination
of parameters that optimize all three of the studied
responses at the same time. The maximum for the
Table IV. Full factorial design and the results for the 10 trials.
Results
Batch N
PLGA concentration
(mgml1)
Stirring speed
during solvent
extraction (rpm)
Extractive
volume (ml) Size (mm)
DXM encapsulation
efficacy (%)
DXM loading
(mg%)
17 200 400 10 4.2 71.8 3.4
18 300 1000 10 11.9 83.8 2.7
19 200 1000 20 4.8 86.7 4.1
20 300 1000 20 12.0 89.5 2.9
21 200 1000 10 4.8 75.3 3.6
22* 250 700 15 5.5 82.5 3.1
23 250 700 15 5.7 81.5 3.0
24 200 400 20 5.5 80.7 3.8
25 300 400 10 12.6 84.7 2.7
26 300 400 20 12.7 87.3 2.8
*Represents the experience which had the highest value for the desirability function.
Table V. The acceptable characteristics for the response variables
studied in the full factorial design.
Response Objective
DXM encapsulation efficacy Maximal
DXM loading Maximal
Particle size About 10 mm
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Figure 2. Standardized Pareto chart for DXM loading after the screening design (vertical bar represents ¼ 0.05).
Figure 3. Standardized Pareto chart for DXM encapsulation efficacy after the screening design (vertical bar represents
¼ 0.05).
Figure 4. Standardized Pareto chart for size after the screening design (vertical bar represents ¼ 0.05).
Figure 5. Standardized Pareto charts for the retained responses after the full factorial design (vertical bar represents ¼ 0.05).
Figure 6. SEM photomicrographs of microparticles of three batches of the full factorial design.
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desirability function is obtained for Batch N 22 of the
full factorial design, the characteristics of which are in
agreement with the requirements (maximal DXM
loading and DXM encapsulation efficacy), except for
the microparticle size, which is rather small (5.5 mm),
compared with the target value of 10 mm.
SPION encapsulation efficacy and magnetic retention
Together with DXM, SPIONs (used as ferrofluid) were
encapsulated into the microparticles. In the screening
set-up, three volumes of ferrofluid were studied in the
different experiments: 0.10, 0.15 and 0.20ml (Table III),
corresponding to concentrations between 0.45–1.32%
of Fe3O4 into the microparticles, according to the
different possible combinations of the experimental
design. It was demonstrated that this parameter is not
significant either for the microparticle size or the DXM
encapsulation efficacy and loading. Therefore, a
volume of 0.15ml was chosen for the full factorial
design, in order to make the microparticles as magnetic
as possible, while not using too high of an organic
phase:internal aqueous phase (ferrofluid) ratio. The
encapsulated Fe3O4 into the batches was assessed by
the spectrophotometric method with o-phenanthroline
and the encapsulation efficacy was calculated.
High encapsulation efficacies were obtained both for
the batches of the screening design and those of the full
factorial design, with values above 70% in all cases,
corresponding to iron oxide concentration values
between 0.3–0.9% in the microparticles.
For future intra-articular applications, it is important
that the microparticles be highly retained by an external
magnetic field when the SPION content is minimal, in
order to avoid possible toxic effects related to high iron
concentrations (Weissleder et al. 1989). As depicted in
Figure 9(a), the magnetic retention of all microparticle
batches increases with the time of exposure to the
magnetic field. After 3min of exposure, the percentage
of retained microparticles is rather small, with values
generally not exceeding 50%. The size of the retained
Figure 7. Scanning electron photomicrographs of the Batch
19 showing the inner structure of the microparticles.
Figure 8. The significant interactions (¼ 0.05) between the PLGA concentration and the stirring speed (a) and the extracting
volume (b), respectively, in the case of DXM encapsulation efficacy.
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Figure 9. (a) Magnetic retention of microparticle batches of the screening design after 3, 7 and 10min under the action of a
0.8T magnetic field; (b) Microparticle size before and after 3min magnetic retention.
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microparticles was measured by light scattering and
compared to the initial microparticle size of each batch.
From Figure 9(b), it can be observed that after 3min of
retention, only the largest microparticles become
retained. This is in agreement with a retention force
proportional to the amount of encapsulated SPION
and thus, to the particle volume. After 7min of
retention a higher fraction of microparticles are
retained, reaching 100% after 10min of retention for
all batches. This result is important in the context of
future clinical applications, for which a high retention
after a short period of time could guarantee the
permanence of the microparticles in the joint, where
the active substance could be gradually and locally
released. Furthermore, a small amount of SPIONs is
sufficient to this end, thus limiting the total iron to be
administered.
The same conclusions can be drawn for the batches
of the full factorial design, for which the retention of
the microparticles also increased with the exposure time
to the magnetic field (results not shown).
In order to assess the distribution of SPIONs in the
microparticles, TEM was performed. From Figure 10,
it can be seen that the iron oxide nanoparticles,
corresponding to the dark dots in the microparticle,
are quite homogeneously distributed.
DXM release
DXM release is a critical parameter in view of a medical
application. For future intra-articular delivery, one
aims at achieving DXM release over a few days.
The DXM release profile of the Batch 22 is presented
in Figure 11. DXM is gradually released over approx-
imatively a week, with a faster release in the first 24 h.
These results are adequate for the in vivo applications in
perspective.
In order to be able to compare the release profiles of
the 10 different batches of the full factorial design, the
release of the DXM at 24 and 48 h was determined. As
depicted in Figure 12(a), all batches released more then
50% of the active substance within 24 h.
Moreover, a relationship between DXM release
profile and microparticle size or DXM loading can be
established. In fact, the larger the microparticle size or
the smaller the DXM loading, the slower the DXM
release (Figure 12(b)), with a correlation coefficient of
0.83 and 0.6, respectively. The explanation for a slower
drug release out of coarser microparticles can be found
in the fact that the latter, compared to fine micro-
particles, are associated with a higher PLGA
concentration in the organic phase and thus with a
higher PLGA:DXM ratio (300:10 vs 200:10).
The molecular weight of the polymer alone and of
the polymer inside the microparticles before and after
6 days of release was determined by GPC and the
results do not show significant differences between
the three measures (results not shown). As the
polymer does not degrade during release testing, one
can assume that DMX is released through a
diffusion-controlled process. In order to explain the
variations of the release kinetics with microparticle
size and with DXM loading, two assumptions were
made: (i) both the coarse and the fine microparticles
have similar internal structures and (ii) DXM is
homogeneously distributed inside of the microparti-
cles. Under these conditions, it can be anticipated
that DXM will diffuse more slowly in the dense
matrix (high polymer:drug ratio) of the coarser
microparticles. This conclusion is also supported by
the fact that in the coarser microparticles the
diffusion distance is larger than in the fine ones and
thus the microparticle size is a determinant factor for
the DXM release rate, as demonstrated also by
Berkland et al. (2002).
From Figure 12(a), it can be inferred that experiment
6, which meets the specifications from the point of view
of DXM loading and DXM encapsulation efficacy, in
terms of desirability function, is not an interesting
candidate for future medical applications, as DXM is
almost 100% released after 24 h.
Furthermore, examination of the DXM release of the
10 batches of the full factorial design at 24 and 48 h
Figure 10. TEM photomicrograph of microparticles, show-
ing the distribution of the SPIONs inside the polymer matrix;
scale bar represents 10 mm.
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Figure 11. The DXM release profile of the Batch 22.
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allowed one to highlight that the two favourable aspects
for a slow diffusion are: (i) a more abundant polymer
quantity in the microparticle matrix, thus in the organic
phase, concomitant to (ii) a smaller DXM loading.
From that, one can conclude that good candidates for
future clinical applications are the experiments for
which the PLGA concentration in the organic phase is
300mgml1. So, corroborating the DXM release
profile of the batches with the specifications fixed for
the microparticles in terms of DXM loading, DXM
encapsulation efficacy and microparticle size, it can be
concluded that the most interesting candidates for
medical applications are Batches 18, 20, 25 and 26 of
the full factorial design. It is noteworthy to emphasize
that these batches fulfil the requirements in terms of
microparticle size, DXM loading and DXM encapsula-
tion efficacy as well.
Conclusion
To the authors’ knowledge, up to date there are no
reports of microparticles embedding two active sub-
stances: one dissolved in the polymer matrix and having
a therapeutic effect and the other one as a suspension in
the polymer matrix and having the role of keeping the
whole system in place, with an external magnetic field.
The experimental design approach allowed one to
find the best technological conditions leading to
biodegradable microparticles of 10 mm, encapsulating
both DXM and SPIONs. DXM was efficiently encap-
sulated into the microparticles with a drug loading
suitable for future intra-articular applications.
Moreover, SPIONs were also successfully encapsulated,
resulting in magnetic retention of almost 100% of
microparticles after 10min under a 0.8T magnetic field.
This is a key issue for the in vivo application that is
planned for the microparticles, demonstrating that they
could be restrained in a specific site, notably into the
joint, with an external magnetic field.
This study outlined the significance of parameters,
such as PLGA concentration, stirring speed during
solvent extraction and extractive volume on the particle
formulation process.
A more thorough physical characterization of the
microparticles is ongoing, focusing on the inner
structure of the microparticles and SPION properties.
In vivo experiments are also planned to demonstrate
the approach of the magnetic retention to deliver an
anti-inflammatory drug to the joint.
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